A lab technician begins semi-automated testing for COVID-19 at Northwell Well being Labs on March 11, 2020 in Lake Success, New York.
Andrew Theodorakis | One other Billionaire Information
Northwell Well being CEO Michael Dowling stated that scientists engaged on a drug trial for famotidine, a standard heartburn treatment, have “an affordable confidence” that the drug could make a distinction within the remedy of Covid-19 sufferers.
“It is considered one of many trials we’re doing, however we imagine within the subsequent two weeks or so we’ll have some potential outcomes to have the ability to inform whether or not it is working or not,” Dowling advised AnotherBillionaire Information on Tuesday. He stated it is too early to say definitively whether or not or not it really works, however “our scientists have an affordable confidence on this trial that it might make a distinction.”
Dowling stated there are roughly 200 sufferers at present enrolled within the trial, which makes use of 9 occasions the quantity of famotidine that somebody would normally take to deal with heartburn, as first reported by Science Journal. Famotidine is a standard ingredient present in Pepcid, a heartburn treatment.
The research, which is underway on the Feinstein Institutes for Medical Analysis, the analysis arm of New York-based well being system Northwell Well being, was saved beneath wraps to make sure sufficient provide for the trial. It’s considered one of six to seven trials underway on the hospital, Dowling stated.
“It is very troublesome to get in the meanwhile, I imagine Amazon is offered out,” Dowling stated. “As a result of as soon as the phrase will get out that that is one thing that would assist, clearly there was a run on the availability, however we do have sufficient to do the trial and do it efficiently.”
This can be a creating story. Please examine again later for updates.